Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.

Saur HajievElias AllaraLeila Motedayеn AvalTadaaki ArizumiDominik BettingerMario PirisiLorenza RimassaTiziana PressianiNicola PersoneniLaura GiordanoMasatoshi KudoRobert ThimmeJoong-Won ParkTamar H TaddeiDavid E KaplanRamya RamaswamiDavid J PinatoRohini Sharma

Published in: British journal of cancer (2020)

Clinical outcomes in the elderly is equivalent to patients aged <75 years, independent of dose of sorafenib prescribed.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
metabolic syndrome
patient reported outcomes
adipose tissue
middle aged
weight loss
community dwelling
glycemic control